The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex

International Journal of Cancer

Volumn 104, Issue 3, 2003, Pages 283-288

  Korver, Wouter ^a,c   Guevara, Claudia ^a   Chen, Yang ^b   Neuteboom, Saskia ^a   Bookstein, Rob ^a   Tavtigian, Sean ^b   Lees, Emma ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Myriad Genetics Laboratories Inc   (United States)

^c Department of Life Sciences   (United States)

Author keywords

ulbulin; Microtubules; Mitosis; Mitotic spindle; Prostate cancer; Susceptibility gene

Indexed keywords

COMPLEMENTARY DNA; GAMMA TUBULIN; GENE PRODUCT; PROTEIN ELAC2; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL DIVISION; CHROMOSOME 17P; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 17; CYCLIN B; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROLASES; IMMUNOBLOTTING; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RABBITS; RISK FACTORS; TRANSFECTION; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0037431434     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10945     Document Type: Article

References (24)

1. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-34.
2. Nupponen NN, Carpten JD. Prostate cancer susceptibility genes: many studies, many results, no answers. Cancer Metastasis Rev 2001;20:155-64.
3. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-80.
4. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001;68:901-11.
5. Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 2001;61:4982-4.
6. Wu YQ, Chen H, Rubin MA, Wojno KJ, Cooney KA. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Cancer Res 2001;61:8651-3.
7. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-9.
8. Rokman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res 2001;61:6038-41.
9. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001;61:6494-9.
10. Vogel A, Schilling O, Niecke M, Bettmer J, Meyer-Klaucke W. ElaC encodes a novel binuclear zinc phosphodiesterase. J Biol Chem 2002;277:29078-85.
11. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996;70:4805-10.
12. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 1995;6:1403-16.
13. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997;8:453-65.
14. Jeng R, Stearns T. Gamma-tubulin complexes: size does matter. Trends Cell Biol 1999;9:339-42.
15. Schiebel E. gamma-tubulin complexes: binding to the centrosome, regulation and microtubule nucleation. Curr Opin Cell Biol 2000;12:113-8.
16. Murphy SM, Urbani L, Stearns T. The mammalian gamma-tubulin complex contains homologues of the yeast spindle pole body components spc97p and spc98p. J Cell Biol 1998;141:663-74.
17. Moudjou M, Bordes N, Paintrand M, Bornens M. gamma-Tubulin in mammalian cells: the centrosomal and the cytosolic forms. J Cell Sci 1996;109(Pt 4):875-87.
18. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, Brown PO, Botstein D, Futcher B. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiale by microarray hybridization. Mol Biol Cell 1998;9:3273-97.
19. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell 1999;91:451-60.
20. Whitehead CM, Salisbury JL. Regulation and regulatory activities of centrosomes. J Cell Biochem 1999;32-33(Suppl):192-9.
21. Khodjakov A, Rieder CL. The sudden recruitment of gamma-tubulin to the centrosome at the onset of mitosis and its dynamic exchange throughout the cell cycle do not require microtubules. J Cell Biol 1999;146:585-96.
22. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-35.
23. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000;408:429-32.
24. Haber D. BRCA1: an emerging role in the cellular response to DNA damage. Lancet 2000;355:2090-1.